Dianthus Therapeutics (DNTH) News Today $18.98 -0.23 (-1.20%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Vanguard Group Inc. Sells 20,331 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Vanguard Group Inc. lessened its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 1.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,274,638 shares of the company's stock after selling 20,331 shares during the quApril 16 at 3:19 AM | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by ADAR1 Capital Management LLCADAR1 Capital Management LLC decreased its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 85.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 17,683 shares of the company's stock after seApril 9, 2025 | marketbeat.comAlliancebernstein L.P. Has $25.28 Million Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Alliancebernstein L.P. boosted its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 13.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,159,776 shares of the company's stock after acquiring anApril 9, 2025 | marketbeat.comBrokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $54.33April 9, 2025 | americanbankingnews.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Rhenman & Partners Asset Management ABRhenman & Partners Asset Management AB lowered its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 24.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 114,000 shares of the coApril 7, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Buy" from BrokeragesDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has received an average recommendation of "Buy" from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and two have issued aApril 7, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase - Still a Buy?Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume - Should You Buy?April 4, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week Low - Should You Sell?Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 1-Year Low - Here's What HappenedApril 2, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Trading Down 7% - Here's What HappenedDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 7% - Here's WhyApril 1, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Trading Up 6.5% - Should You Buy?Dianthus Therapeutics (NASDAQ:DNTH) Trading 6.5% Higher - Here's WhyMarch 28, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Hits New 52-Week Low - What's Next?Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year Low - Here's What HappenedMarch 27, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Trading Down 3.8% - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.8% - Here's What HappenedMarch 18, 2025 | marketbeat.comFY2025 EPS Estimates for DNTH Raised by Cantor FitzgeraldDianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Stock analysts at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for Dianthus Therapeutics in a research note issued to investors on Thursday, March 13th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the cMarch 17, 2025 | marketbeat.comHC Wainwright Issues Optimistic Outlook for DNTH EarningsDianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Investment analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for Dianthus Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst S. Ramakanth now forecMarch 17, 2025 | marketbeat.comWhat is Lifesci Capital's Estimate for DNTH FY2025 Earnings?Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at Lifesci Capital increased their FY2025 earnings estimates for shares of Dianthus Therapeutics in a research note issued to investors on Wednesday, March 12th. Lifesci Capital analyst R. Katkhuda now expects that the coMarch 15, 2025 | marketbeat.comWedbush Analysts Decrease Earnings Estimates for DNTHDianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at Wedbush decreased their Q1 2025 EPS estimates for shares of Dianthus Therapeutics in a research note issued on Wednesday, March 12th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.74) per sharMarch 15, 2025 | marketbeat.comStifel maintains Buy rating on Dianthus Therapeutics stockMarch 14, 2025 | uk.investing.comDianthus Therapeutics shares fall as Q4 results miss expectationsMarch 14, 2025 | investing.comWe're Not Very Worried About Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn RateMarch 13, 2025 | finance.yahoo.comDianthus Therapeutics Full Year 2024 Earnings: Beats ExpectationsMarch 13, 2025 | finance.yahoo.comDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - What's Next?March 13, 2025 | marketbeat.comWedbush Reaffirms Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH)Wedbush reiterated an "outperform" rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday.March 13, 2025 | marketbeat.comDianthus Therapeutics' (DNTH) "Buy" Rating Reaffirmed at GuggenheimGuggenheim reaffirmed a "buy" rating and set a $84.00 target price on shares of Dianthus Therapeutics in a report on Wednesday.March 13, 2025 | marketbeat.comDianthus Therapeutics' (DNTH) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday.March 13, 2025 | marketbeat.comDianthus Therapeutics (DNTH) to Release Quarterly Earnings on ThursdayDianthus Therapeutics (NASDAQ:DNTH) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comDianthus Therapeutics Reports 2024 Financial Results and Clinical ProgressMarch 13, 2025 | tipranks.comDianthus Therapeutics (NASDAQ:DNTH) Announces Earnings Results, Beats Estimates By $0.04 EPSDianthus Therapeutics (NASDAQ:DNTH - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.March 12, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% - Time to Sell?Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5% - What's Next?March 12, 2025 | marketbeat.comDianthus reports Q4 EPS (81c), consensus (76c)March 12, 2025 | markets.businessinsider.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by BrokeragesDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine analysts that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and two have issued a stMarch 12, 2025 | marketbeat.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial ResultsMarch 11, 2025 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Trading 8.2% Higher - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Trading 8.2% Higher - What's Next?March 6, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month Low - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Hits New 12-Month Low - Should You Sell?March 5, 2025 | marketbeat.comDianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of DirectorsMarch 5, 2025 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.3% - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.3% - Time to Sell?March 3, 2025 | marketbeat.comDianthus Therapeutics to Participate in Two Upcoming Investor ConferencesFebruary 26, 2025 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.6% - Here's What HappenedDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.6% - What's Next?February 24, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by AnalystsShares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have been assigned an average recommendation of "Buy" from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and two hFebruary 15, 2025 | marketbeat.comStifel Nicolaus Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)February 10, 2025 | markets.businessinsider.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 8% - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Trading 8% Higher - Here's What HappenedFebruary 5, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 6.0% in JanuaryDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 6,000,000 shares, an increase of 6.0% from the December 31st total of 5,660,000 shares. Based on an average trading volume of 250,800 shares, the days-to-cover ratio is currently 23.9 days. Approximately 31.2% of the shares of the company are sold short.February 4, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Increase in Short InterestDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 6,000,000 shares, a growth of 6.0% from the December 31st total of 5,660,000 shares. Based on an average trading volume of 250,800 shares, the days-to-cover ratio is presently 23.9 days. Currently, 31.2% of the shares of the stock are sold short.February 3, 2025 | marketbeat.comDianthus Therapeutics to Webcast Presentations at Two Investor ConferencesJanuary 30, 2025 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.6% - Here's WhyDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.6% - Here's What HappenedJanuary 23, 2025 | marketbeat.comCantor Fitzgerald Forecasts DNTH FY2025 EarningsDianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Dianthus Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts thatJanuary 22, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by AnalystsDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been assigned a consensus rating of "Buy" from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy ratingJanuary 21, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Growth in Short InterestDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 6,000,000 shares, an increase of 6.0% from the December 15th total of 5,660,000 shares. Based on an average trading volume of 250,800 shares, the days-to-cover ratio is currently 23.9 days. Approximately 31.2% of the company's stock are short sold.January 19, 2025 | marketbeat.comBarclays PLC Acquires 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Barclays PLC raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 390.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,684 shares of the company's stock after acquiring an additional 33,185January 14, 2025 | marketbeat.comDianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.8% - Should You Sell?Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 6.8% - Here's WhyJanuary 7, 2025 | marketbeat.com Remove Ads Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address DNTH Media Mentions By Week DNTH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNTH News Sentiment▼1.170.79▲Average Medical News Sentiment DNTH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNTH Articles This Week▼23▲DNTH Articles Average Week Remove Ads Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vericel News Bausch Health Companies News Biohaven News Tarsus Pharmaceuticals News Ascentage Pharma Group International News Belite Bio News NewAmsterdam Pharma News Metsera News Arcutis Biotherapeutics News Recursion Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNTH) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
